Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, John M. Kirkwood et al.|New England Journal of Medicine|2020Cited by 406
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, T Haas et al.|Journal of Clinical Oncology|2018Cited by 255
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Georgina V. Long, John M. Kirkwood et al.|The Lancet Oncology|2019Cited by 56
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III <i>BRAF</i> V600–mutant melanoma: Five-year analysis of COMBI-AD.Axel Hauschild, Dirk Schadendorf, John M. Kirkwood et al.|Journal of Clinical Oncology|2020Cited by 23